The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is limited as these subtypes are relatively rare compared to cutaneous melanoma (CM).

[1]  S. Fukushima,et al.  Anti-PD1 checkpoint inhibitor therapy in acral melanoma: A multicentre study of 193 Japanese patients. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Schadendorf,et al.  Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). , 2019, European journal of cancer.

[3]  Yanhong Gu,et al.  A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151) , 2019, Translational oncology.

[4]  James R. Anderson,et al.  Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Catherine A. Shang,et al.  Whole-genome landscapes of major melanoma subtypes , 2017, Nature.

[6]  K. Savage,et al.  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Sullivan,et al.  The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma , 2016, Cancer.

[8]  J. Wolchok,et al.  Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. , 2016, The oncologist.

[9]  Y. Fujisawa,et al.  Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. , 2015, Journal of dermatological science.

[10]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[11]  J. Larkin,et al.  Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients , 2015, Melanoma research.

[12]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[13]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[14]  G. Stamp,et al.  The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis , 2014, Pigment cell & melanoma research.

[15]  R. Sullivan,et al.  Understanding the biology of melanoma and therapeutic implications. , 2014, Hematology/oncology clinics of North America.

[16]  B. Bastian.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. , 2014, Annual review of pathology.

[17]  D. Coit,et al.  Prognosis of Acral Melanoma: A Series of 281 Patients , 2013, Annals of Surgical Oncology.

[18]  G. Stamp,et al.  Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma , 2013, The Journal of pathology.

[19]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[20]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[22]  Ahmedin Jemal,et al.  Incidence of noncutaneous melanomas in the U.S. , 2005, Cancer.

[23]  E. Dupin,et al.  Development of melanocyte precursors from the vertebrate neural crest , 2003, Oncogene.

[24]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[25]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[26]  B K Armstrong,et al.  Melanoma of the skin. , 1984, British medical bulletin.